Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms

Cell

Volumn 170, Issue 1, 2017, Pages 199-212.e20

  Rusu, Victor ^a,b,l   Hoch, Eitan ^b   Mercader, Josep M ^b,c,d,k   Gymrek, Melissa ^b,c,m   von Grotthuss, Marcin ^b   Fontanillas, Pierre ^b,n   Spooner, Alexandra ^b   Altshuler, David M ^a,b,c,j,k,o   Florez, Jose C ^a,b,c,k   Jacobs, Suzanne B R ^b,c   Clish, Clary B ^b   Tenen, Danielle E ^b,e   Hartigan, Christina R ^b   DeRan, Michael ^b   Guzman, Gaelen ^b   Deik, Amy A ^b   Pierce, Kerry A ^b   Dennis, Courtney ^b   Carr, Steven A ^b   Wagner, Bridget K ^b   Schenone, Monica ^b   Schreiber, Stuart L ^b   Lander, Eric S ^a,b,j   Ng, Maggie C Y ^f,k   Chen, Brian H ^g,k   Centeno Cruz, Federico ^h,k   Orozco, Lorena ^h,k   Zerrweck, Carlos ^i,k   Shriner, Daniel ^k   Li, Jiang ^k   Chen, Wei Min ^k   Guo, Xiuqing ^k   Liu, Jiankang ^k   Bielinski, Suzette J ^k   Yanek, Lisa R ^k   Nalls, Michael A ^k   Comeau, Mary E ^k   Rasmussen Torvik, Laura J ^k   Jensen, Richard A ^k   Evans, Daniel S ^k   Sun, Yan V ^k   An, Ping ^k   Patel, Sanjay R ^k   Lu, Yingchang ^k   Long, Jirong ^k   Armstrong, Loren L ^k   Wagenknecht, Lynne ^k   Yang, Lingyao ^k   Snively, Beverly M ^k   Palmer, Nicholette D ^k   Mudgal, Poorva ^k   Keene, Keith L ^k   Freedman, Barry I ^k   Mychaleckyj, Josyf C ^k   Nayak, Uma ^k   Raffel, Leslie J ^k   Goodarzi, Mark O ^k   Chen, Y D Ida ^k   Taylor, Herman A ^k   Correa, Adolfo ^k   Sims, Mario ^k   Couper, David ^k   Pankow, James S ^k   Boerwinkle, Eric ^k   Adeyemo, Adebowale ^k   Doumatey, Ayo ^k   Chen, Guanjie ^k   Mathias, Rasika A ^k   Vaidya, Dhananjay ^k   Singleton, Andrew B ^k   Zonderman, Alan B ^k   Igo, Robert P ^k   Sedor, John R ^k   Kabagambe, Edmond K ^k   Siscovick, David S ^k   McKnight, Barbara ^k   Rice, Kenneth ^k   Liu, Yongmei ^k   Hsueh, Wen Chi ^k   Zhao, Wei ^k   Bielak, Lawrence F ^k   Kraja, Aldi ^k   Province, Michael A ^k   Bottinger, Erwin P ^k   Gottesman, Omri ^k   Cai, Qiuyin ^k   Zheng, Wei ^k   Blot, William J ^k   Lowe, William L ^k   Pacheco, Jennifer A ^k   Crawford, Dana C ^k   Grundberg, Elin ^k   Rich, Stephen S ^k   Hayes, M Geoffrey ^k   Shu, Xiao Ou ^k   Loos, Ruth J F ^k   Borecki, Ingrid B ^k   Peyser, Patricia A ^k   Cummings, Steven R ^k   Psaty, Bruce M ^k   Fornage, Myriam ^k   Iyengar, Sudha K ^k   Evans, Michele K ^k   Becker, Diane M ^k   Kao, W H Linda ^k   Wilson, James G ^k   Rotter, Jerome I ^k   Sale, Michèle M ^k   Liu, Simin ^k   Rotimi, Charles N ^k   Bowden, Donald W ^k   Huerta Chagoya, Alicia ^k   García Ortiz, Humberto ^k   Moreno Macías, Hortensia ^k   Manning, Alisa ^k   Caulkins, Lizz ^k   Burtt, Noël P ^k   Flannick, Jason ^k   Patterson, Nick ^k   Aguilar Salinas, Carlos A ^k   Tusié Luna, Teresa ^k   Martínez Hernández, Angélica ^k   Barajas Olmos, Francisco Martin ^k   Contreras Cubas, Cecilia ^k   Mendoza Caamal, Elvia ^k   Revilla Monsalve, Cristina ^k   Islas Andrade, Sergio ^k   Córdova, Emilio ^k   Soberón, Xavier ^k   González Villalpando, Clicerio ^k   González Villalpando, María Elena ^k   Haiman, Christopher A ^k   Wilkens, Lynne ^k   Le Marchand, Loic ^k   Monroe, Kristine ^k   Kolonel, Laurence ^k   Arellano Campos, Olimpia ^k   Ordóñez Sánchez, Maria L ^k   Rodríguez Torres, Maribel ^k   Segura Kato, Yayoi ^k   Rodríguez Guillén, Rosario ^k   Cruz Bautista, Ivette ^k   Muñoz Hernandez, Linda Liliana ^k   Sáenz, Tamara ^k   Gómez, Donají ^k   Alvirde, Ulices ^k   Almeda Valdés, Paloma ^k   Cortes, Maria L ^k   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g NATIONAL INSTITUTE ON AGING   (United States)

^h INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

ⁱ Delegación Tláhuac   (Mexico)

^j MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^k MIT ^*

^l Jnana Therapeutics   (United States)

^m UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁿ 23andMe ^*  (United States)

^o VERTEX PHARMACEUTICALS   (United States)

more..

Author keywords

disease mechanism; fatty acid metabolism; genetics; lipid metabolism; MCT11; monocarboxylates; precision medicine; SLC16A11; solute carrier (SLC); type 2 diabetes (T2D)

Indexed keywords

MONOCARBOXYLATE TRANSPORTER; PROATEIN SLC16A11; PROTEIN; UNCLASSIFIED DRUG; BSG PROTEIN, HUMAN; CD147 ANTIGEN; SLC16A11 PROTEIN, HUMAN;

ARTICLE; CELL METABOLISM; CELL SURFACE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; CELL MEMBRANE; CHEMISTRY; CHROMOSOME 17; GENE SILENCING; GENETICS; HISTONE CODE; LIVER; LIVER CELL; METABOLISM; MOLECULAR MODEL;

ANTIGENS, CD147; CELL MEMBRANE; CHROMOSOMES, HUMAN, PAIR 17; DIABETES MELLITUS, TYPE 2; GENE KNOCKDOWN TECHNIQUES; HAPLOTYPES; HEPATOCYTES; HETEROZYGOTE; HISTONE CODE; HUMANS; LIVER; MODELS, MOLECULAR; MONOCARBOXYLIC ACID TRANSPORTERS;

EID: 85021628341     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.06.011     Document Type: Article

References (63)

1. Adams, S.H., Hoppel, C.L., Lok, K.H., Zhao, L., Wong, S.W., Minkler, P.E., Hwang, D.H., Newman, J.W., Garvey, W.T., Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J. Nutr. 139 (2009), 1073–1081.
2. Bernstein, B.E., Kamal, M., Lindblad-Toh, K., Bekiranov, S., Bailey, D.K., Huebert, D.J., McMahon, S., Karlsson, E.K., Kulbokas, E.J. 3rd, Gingeras, T.R., et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120 (2005), 169–181.
3. Cohen, J.C., Boerwinkle, E., Mosley, T.H. Jr., Hobbs, H.H., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354 (2006), 1264–1272.
4. Delaneau, O., Zagury, J.F., Marchini, J., Improved whole-chromosome phasing for disease and population genetic studies. Nat. Methods 10 (2013), 5–6.
5. Diamond, J., The double puzzle of diabetes. Nature 423 (2003), 599–602.
6. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489 (2012), 57–74.
7. Erion, D.M., Shulman, G.I., Diacylglycerol-mediated insulin resistance. Nat. Med. 16 (2010), 400–402.
8. Estrada, K., Aukrust, I., Bjørkhaug, L., Burtt, N.P., Mercader, J.M., García-Ortiz, H., Huerta-Chagoya, A., Moreno-Macías, H., Walford, G., Flannick, J., et al., SIGMA Type 2 Diabetes Consortium. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA 311 (2014), 2305–2314.
9. Flannick, J., Florez, J.C., Type 2 diabetes: genetic data sharing to advance complex disease research. Nat. Rev. Genet. 17 (2016), 535–549.
10. Flannick, J., Thorleifsson, G., Beer, N.L., Jacobs, S.B., Grarup, N., Burtt, N.P., Mahajan, A., Fuchsberger, C., Atzmon, G., Benediktsson, R., et al. Go-T2D Consortium, T2D-GENES Consortium. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat. Genet. 46 (2014), 357–363.
11. Gloyn, A.L., Pearson, E.R., Antcliff, J.F., Proks, P., Bruining, G.J., Slingerland, A.S., Howard, N., Srinivasan, S., Silva, J.M., Molnes, J., et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 350 (2004), 1838–1849.
12. Halestrap, A.P., The SLC16 gene family - structure, role and regulation in health and disease. Mol. Aspects Med. 34 (2013), 337–349.
13. Hara, K., Fujita, H., Johnson, T.A., Yamauchi, T., Yasuda, K., Horikoshi, M., Peng, C., Hu, C., Ma, R.C., Imamura, M., et al., DIAGRAM consortium. Genome-wide association study identifies three novel loci for type 2 diabetes. Hum. Mol. Genet. 23 (2014), 239–246.
14. Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., Singh, H., Glass, C.K., Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38 (2010), 576–589.
15. Hugo, S.E., Cruz-Garcia, L., Karanth, S., Anderson, R.M., Stainier, D.Y., Schlegel, A., A monocarboxylate transporter required for hepatocyte secretion of ketone bodies during fasting. Genes Dev. 26 (2012), 282–293.
16. Inzucchi, S.E., Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287 (2002), 360–372.
17. Kurowski, M.A., Bujnicki, J.M., GeneSilico protein structure prediction meta-server. Nucleic Acids Res. 31 (2003), 3305–3307.
18. Langmead, B., Salzberg, S.L., Fast gapped-read alignment with Bowtie 2. Nat. Methods 9 (2012), 357–359.
19. Lemieux, M.J., Song, J., Kim, M.J., Huang, Y., Villa, A., Auer, M., Li, X.D., Wang, D.N., Three-dimensional crystallization of the Escherichia coli glycerol-3-phosphate transporter: a member of the major facilitator superfamily. Protein Sci. 12 (2003), 2748–2756.
20. Locke, J.M., Hysenaj, G., Wood, A.R., Weedon, M.N., Harries, L.W., Targeted allelic expression profiling in human islets identifies cis-regulatory effects for multiple variants identified by type 2 diabetes genome-wide association studies. Diabetes 64 (2015), 1484–1491.
21. Manoharan, C., Wilson, M.C., Sessions, R.B., Halestrap, A.P., The role of charged residues in the transmembrane helices of monocarboxylate transporter 1 and its ancillary protein basigin in determining plasma membrane expression and catalytic activity. Mol. Membr. Biol. 23 (2006), 486–498.
22. Maurano, M.T., Humbert, R., Rynes, E., Thurman, R.E., Haugen, E., Wang, H., Reynolds, A.P., Sandstrom, R., Qu, H., Brody, J., et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 337 (2012), 1190–1195.
23. Mihalik, S.J., Goodpaster, B.H., Kelley, D.E., Chace, D.H., Vockley, J., Toledo, F.G., DeLany, J.P., Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 18 (2010), 1695–1700.
24. Mikkelsen, T.S., Ku, M., Jaffe, D.B., Issac, B., Lieberman, E., Giannoukos, G., Alvarez, P., Brockman, W., Kim, T.K., Koche, R.P., et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448 (2007), 553–560.
25. Moltke, I., Grarup, N., Jørgensen, M.E., Bjerregaard, P., Treebak, J.T., Fumagalli, M., Korneliussen, T.S., Andersen, M.A., Nielsen, T.S., Krarup, N.T., et al. A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Nature 512 (2014), 190–193.
26. Morris, A.P., Voight, B.F., Teslovich, T.M., Ferreira, T., Segrè, A.V., Steinthorsdottir, V., Strawbridge, R.J., Khan, H., Grallert, H., Mahajan, A., et al. Wellcome Trust Case Control Consortium Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators Genetic Investigation of ANthropometric Traits (GIANT) Consortium Asian Genetic Epidemiology Network–Type 2 Diabetes (AGEN-T2D) Consortium South Asian Type 2 Diabetes (SAT2D) Consortium, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 44 (2012), 981–990.
27. Nauck, M.A., Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des. Devel. Ther. 8 (2014), 1335–1380.
28. Neel, J.V., Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”?. Am. J. Hum. Genet. 14 (1962), 353–362.
29. Nelson, M.R., Tipney, H., Painter, J.L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P.C., Li, M.J., Wang, J., et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47 (2015), 856–860.
30. Ng, M.C., Shriner, D., Chen, B.H., Li, J., Chen, W.M., Guo, X., Liu, J., Bielinski, S.J., Yanek, L.R., Nalls, M.A., et al. FIND Consortium eMERGE Consortium DIAGRAM Consortium MuTHER Consortium, MEta-analysis of type 2 DIabetes in African Americans Consortium. Meta-analysis of genome-wide association studies in African Americans provides insights into the genetic architecture of type 2 diabetes. PLoS Genet., 10, 2014, e1004517.
31. Ovens, M.J., Davies, A.J., Wilson, M.C., Murray, C.M., Halestrap, A.P., AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem. J. 425 (2010), 523–530.
32. Pearson, E.R., Starkey, B.J., Powell, R.J., Gribble, F.M., Clark, P.M., Hattersley, A.T., Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362 (2003), 1275–1281.
33. Perry, R.J., Samuel, V.T., Petersen, K.F., Shulman, G.I., The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510 (2014), 84–91.
34. Plenge, R.M., Scolnick, E.M., Altshuler, D., Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 12 (2013), 581–594.
35. Prasad, R.B., Groop, L., Genetics of type 2 diabetes-pitfalls and possibilities. Genes (Basel) 6 (2015), 87–123.
36. Rappsilber, J., Mann, M., Ishihama, Y., Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2 (2007), 1896–1906.
37. Rhee, E.P., Cheng, S., Larson, M.G., Walford, G.A., Lewis, G.D., McCabe, E., Yang, E., Farrell, L., Fox, C.S., O'Donnell, C.J., et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J. Clin. Invest. 121 (2011), 1402–1411.
38. Rink, T.J., Tsien, R.Y., Pozzan, T., Cytoplasmic pH and free Mg2+ in lymphocytes. J. Cell Biol. 95 (1982), 189–196.
39. Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E.S., Langslet, G., Raal, F.J., El Shahawy, M., et al., ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372 (2015), 1489–1499.
40. Rui, L., Energy metabolism in the liver. Compr. Physiol. 4 (2014), 177–197.
41. Rychlewski, L., Jaroszewski, L., Li, W., Godzik, A., Comparison of sequence profiles. Strategies for structural predictions using sequence information. Protein Sci. 9 (2000), 232–241.
42. Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., Raal, F.J., Blom, D.J., Robinson, J., Ballantyne, C.M., Somaratne, R., Legg, J., Wasserman, S.M., et al., Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372 (2015), 1500–1509.
43. Sali, A., Blundell, T.L., Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234 (1993), 779–815.
44. Samuel, V.T., Shulman, G.I., Mechanisms for insulin resistance: common threads and missing links. Cell 148 (2012), 852–871.
45. San Martín, A., Ceballo, S., Baeza-Lehnert, F., Lerchundi, R., Valdebenito, R., Contreras-Baeza, Y., Alegría, K., Barros, L.F., Imaging mitochondrial flux in single cells with a FRET sensor for pyruvate. PLoS ONE, 9, 2014, e85780.
46. Sanjana, N.E., Shalem, O., Zhang, F., Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11 (2014), 783–784.
47. Seymour, C.A., Byrne, C.D., Triglycerides and disease. Postgrad. Med. J. 69 (1993), 679–695.
48. Shepherd, M., Shields, B., Ellard, S., Rubio-Cabezas, O., Hattersley, A.T., A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet. Med. 26 (2009), 437–441.
49. Sievers, F., Wilm, A., Dineen, D., Gibson, T.J., Karplus, K., Li, W., Lopez, R., McWilliam, H., Remmert, M., Söding, J., et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol., 7, 2011, 539.
50. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
51. Suhre, K., Shin, S.Y., Petersen, A.K., Mohney, R.P., Meredith, D., Wägele, B., Altmaier, E., Deloukas, P., Erdmann, J., Grundberg, E., et al., CARDIoGRAM. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477 (2011), 54–60.
52. Traurig, M., Hanson, R.L., Marinelarena, A., Kobes, S., Piaggi, P., Cole, S., Curran, J.E., Blangero, J., Göring, H., Kumar, S., et al. Analysis of SLC16A11 Variants in 12,811 American Indians: Genotype-Obesity Interaction for Type 2 Diabetes and an Association With RNASEK Expression. Diabetes 65 (2016), 510–519.
53. van de Geijn, B., McVicker, G., Gilad, Y., Pritchard, J.K., WASP: allele-specific software for robust molecular quantitative trait locus discovery. Nat. Methods 12 (2015), 1061–1063.
54. Van Goor, F., Yu, H., Burton, B., Hoffman, B.J., Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J. Cyst. Fibros. 13 (2014), 29–36.
55. Villalpando, S., de la Cruz, V., Rojas, R., Shamah-Levy, T., Avila, M.A., Gaona, B., Rebollar, R., Hernández, L., Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population: a probabilistic survey. Salud Publica Mex. 52:Suppl 1 (2010), S19–S26.
56. Visser, W.E., Philp, N.J., van Dijk, T.B., Klootwijk, W., Friesema, E.C., Jansen, J., Beesley, P.W., Ianculescu, A.G., Visser, T.J., Evidence for a homodimeric structure of human monocarboxylate transporter 8. Endocrinology 150 (2009), 5163–5170.
57. Voight, B.F., Scott, L.J., Steinthorsdottir, V., Morris, A.P., Dina, C., Welch, R.P., Zeggini, E., Huth, C., Aulchenko, Y.S., Thorleifsson, G., et al. MAGIC investigators, GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat. Genet. 42 (2010), 579–589.
58. von Grotthuss, M., Pas, J., Wyrwicz, L., Ginalski, K., Rychlewski, L., Application of 3D-Jury, GRDB, and Verify3D in fold recognition. Proteins 53:Suppl 6 (2003), 418–423.
59. Wainwright, C.E., Elborn, J.S., Ramsey, B.W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J.C., De Boeck, K., Flume, P.A., et al. TRAFFIC Study Group, TRANSPORT Study Group. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N. Engl. J. Med. 373 (2015), 220–231.
60. Wajner, M., Amaral, A.U., Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies. Biosci. Rep., 36, 2015, e00281.
61. Wakefield, J., A Bayesian measure of the probability of false discovery in genetic epidemiology studies. Am. J. Hum. Genet. 81 (2007), 208–227.
62. Willer, C.J., Li, Y., Abecasis, G.R., METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26 (2010), 2190–2191.
63. Williams, A.L., Jacobs, S.B., Moreno-Macías, H., Huerta-Chagoya, A., Churchhouse, C., Márquez-Luna, C., García-Ortíz, H., Gómez-Vázquez, M.J., Burtt, N.P., Aguilar-Salinas, C.A., et al., SIGMA Type 2 Diabetes Consortium. Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico. Nature 506 (2014), 97–101.